2385-26-4

Basic information

• Product Name: Benzamide, N-(4-bromophenyl)-2-nitro-
• CAS NO: 2385-26-4
• Molecular Formula: C13H9BrN2O3
• Molecular Weight: 321.13
• Mol File: 2385-26-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzamide, N-(4-bromophenyl)-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N-(4-bromophenyl)-2-nitro-(2385-26-4)
• EPA Substance Registry System: Benzamide, N-(4-bromophenyl)-2-nitro-(2385-26-4)

Safety Data

• Hazardous Substances Data: 2385-26-4(Hazardous Substances Data)

Upstream product

• 106-40-1 4-bromo-aniline 
• 610-14-0 2-nitrobenzyl chloride 
• 552-16-9 ortho-nitrobenzoic acid 

Downstream Products

• 135066-31-8 2-(4-Bromo-phenyl)-1,2-dihydro-indazol-3-one 
• 50735-55-2 2-amino-N-(4-bromophenyl)benzamide 
• 1028-40-6 3-(4-chlorophenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one 
• 1350616-37-3 3'-(4-bromophenyl)-1'H,2H-spiro[acenaphthylene-1,2'-quinazoline]-2,4'(3'H)-dione 
• 306319-09-5 N-(4-bromophenyl)-2-((thiophen-2-yl)carbonylamino)benzamide 
• 19857-47-7 3-(4-bromophenyl)-2-phenylquinazolin-4(3H)-one 
• 2400-96-6 3-(p-Bromphenyl)-2,4-dioxotetrahydrochinazolin 
• 84770-66-1 2,2-Dimethyl-3-(4'-bromophenyl)-1,2,3,4-tetrahydroquinazolin-4-one 

Relevant articles and documents

Synthesis and biological evaluation of novel benodanil-heterocyclic carboxamide hybrids as a potential succinate dehydrogenase inhibitors

In order to discover new antifungal agents, twenty novel benodanil-heterocyclic carboxamide hybrids were designed, synthesized, and characterized by 1H NMR and HRMS. In vitro, their antifungal activities against four phytopathogenic fungi were

Scaffold identification of a new class of potent and selective BCRP inhibitors

We recently reported the synthesis and quantitative structure-activity relationships of a new breast cancer resistance protein (BCRP) inhibitor class. In the study presented herein, we investigated the possibility to better define the scaffold of this compound class by removing or modifying the aromatic ring A with various substituents selected on the basis of their electronic and lipophilic properties. The results show that this aromatic ring is important, but not essential, for activity. Many of the selected substituents led to compounds with low activity, but in some cases activity was retained. Among these, a phenolic hydroxy group proved to impart as much potency to the molecule as a hydroxyethyl side chain, initially considered necessary for activity. This derivative is one of the most active compounds in this class, maintaining an inhibitory activity similar to that of the reference compound; it is also selective for BCRP.

QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS

This invention is directed to compounds of formula (I): wherein (A), n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.